<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216138</url>
  </required_header>
  <id_info>
    <org_study_id>HOG HN02-40</org_study_id>
    <nct_id>NCT00216138</nct_id>
  </id_info>
  <brief_title>Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head &amp; Neck</brief_title>
  <official_title>A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent progress in treatment of recurrent/metastatic SCCHN has been made with the
      introduction of the taxanes. Docetaxel as a single agent has a response rate of 22-42% and
      17% in patients with recurrent disease. Capecitabine is an oral fluoropyrimidine prodrug that
      is converted into 5-FU. Previous studies have shown that the capecitabine/docetaxel
      combination has a synergistic inhibition of tumor growth, resulting in significantly superior
      efficacy in time to disease progression (TTP), overall survival, median survival and
      objective tumor response rate compared to docetaxel alone.

      This trial will investigate the efficacy the combination of docetaxel and capecitabine in
      treating patients with recurrent/metastatic SCCHN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Dexamethasone and antiemetic premedication1.

        -  Docetaxel: 60 mg/m2 for a 60 minute infusion day 1 of each cycle

        -  Capecitabine: 825 mg/m2 po BID Days 1-14

      Repeat every 21 days until tumor progression or toxicity that requires discontinuation of
      therapy

      Performance status: ECOG performance status 0 or 1

      Life expectancy: At least 3 months

      Hematopoietic:

        -  ANC of &gt; 1,500/mm3

        -  Platelets &gt; 100,000/mm3

        -  Hemoglobin &gt; 8 gm/dl

      Hepatic:

        -  Total Bilirubin Â£ ULN

        -  Albumin &gt; 3

        -  Maximum Alk Phos &gt; 2.5 x &lt; 5 x ULN

      Renal:

        -  Creatinine clearance of &gt; 50 ml/ min (by Cockcroft-Gault)

      Cardiovascular:

        -  No decompensated congestive heart failure or active angina.

        -  Clinically significant cardiac disease not well controlled with medication (eg.
           congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias)
           or myocardial infarction in the past 12 months is not allowed.

      Pulmonary:

        -  Not specified
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis results did not meet criteria for second stage of trial
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To assess response rate in a group of patients receiving combination therapy with docetaxel and capecitabine</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess toxicity of the combination</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether the status of calpain, calpain activation,(EGFR) expression, Cox-2 expression, TS, TP, DPD, and/or CYP3A4/CYP3A5 will predict treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety analyses on special sub-cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free survival and overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess change in analgesic usage with this protocol therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825 mg/m2 po bid, days 1-14</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premedication</intervention_name>
    <description>Dexamethasone and antiemetic premedication</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head
             and neck.

          -  Recurrent/metastatic disease not amenable to surgery or salvage chemoradiation.

          -  Unidimensional measurable disease according to the RECIST

          -  In-field recurrence, within a prior radiation field only, distant metastatic disease

          -  Both in-field and metastatic sites of disease will require evaluation by a Radiation
             Oncologist to consider local radiation therapy first and will be eligible for possible
             enrollment one month after completion of the radiation therapy.

          -  Negative pregnancy test

          -  Patients may have received prior chemotherapy as part of chemoradiation or induction
             chemotherapy for initial treatment of disease confined to the head and neck region -
             Patients must have fully recovered from any prior radiation therapy

        Exclusion Criteria:

          -  Patients who have relapsed &lt; 6 months after completing a combined modality curative
             treatment that included a fluoropyrimidine or taxanes

          -  No brain metastases

          -  No major neurological disease, including stroke

          -  No prior chemotherapy regimen for recurrent/metastatic disease

          -  No prior history of capecitabine usage

          -  No prior history of docetaxel usage except in the induction setting for head and neck
             cancer which has been completed for greater than 6 months prior to beginning protocol
             therapy

          -  No past hypersensitivity to taxanes or 5 FU

          -  No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80

          -  No current use of warfarin

          -  Patients must not be receiving ketoconazole, midazolam, erythromycin, orphenadrine,
             troleandomycin, cyclosporine or antiepileptics

          -  Patients must not be treated with any of the following on protocol therapy or within
             28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine,
             allopurinol

          -  Patients must have fully recovered from any prior surgery

          -  No known HIV seropositivity.

          -  No serious uncontrolled medical condition, uncontrolled peptic ulcer disease or
             malabsorption syndrome

          -  No peripheral neuropathy &gt; grade 1

          -  Patients with a percutaneous gastrostomy (PEG) must be able take medications by tube.

          -  No daily consumption of alcohol

          -  No active infection

          -  No prior history of malignancy in the last 5 years, excluding in situ carcinoma of the
             cervix or adequately treated basal or squamous cell carcinoma of the skin or Gleason
             Grade &lt; VII organ confined prostate cancer.

          -  No current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Potter, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen Health System</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46527</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care, Inc., P.C.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology-Oncology of S Michigan</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>David Potter, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

